Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians

Area of Science:

• Infectious Diseases
• Microbiology
• Cardiovascular Surgery

Background:

• Mycobacterium chimaera infections pose a risk to patients undergoing open heart surgery.
• Contaminated heater-cooler units are a source of M. chimaera transmission.
• Diagnosis is challenging due to variable incubation periods and nonspecific symptoms.

Purpose of the Study:

• To outline the diagnostic and therapeutic challenges of Mycobacterium chimaera infections.
• To emphasize the importance of combination pharmacologic therapy.
• To highlight the critical role of managing drug-drug interactions.

Main Methods:

• Review of clinical presentation and diagnostic approaches for M. chimaera infections.
• Analysis of recommended first-line and second-line pharmacologic treatments.
• Evaluation of in vitro susceptibility data.
• Identification of common drug-drug interactions with M. chimaera treatment regimens.

Main Results:

• Combination therapy including a macrolide, rifamycin, ethambutol, and amikacin is the standard of care.
• In vitro susceptibility patterns are comparable to other Mycobacterium avium complex species.
• Drug-drug interactions are frequent due to patient comorbidities and polypharmacy.

Conclusions:

• Effective treatment of Mycobacterium chimaera requires aggressive surgical management and combination pharmacologic therapy.
• Careful consideration and management of drug-drug interactions are essential for optimizing patient outcomes.
• Early recognition and appropriate therapeutic strategies are key to combating these challenging infections.